<DOC>
	<DOCNO>NCT01775618</DOCNO>
	<brief_summary>Hemophilia A inherited blood disorder one protein , Factor VIII , need form blood clot miss present sufficient level . Hemophilia A cause clot process slow person experience bleed cause serious problem could lead disability . The current standard treatment severe hemophilia A infusion FVIII stop bleeding , regular schedule treatment prevent bleeds occur . Due short half-life FVIII , prophylaxis may require treatment often every day . In trial safety efficacy long-acting recombinant Factor VIII molecule evaluate 50 male subject , &lt; 12 year age , severe Hemophilia A . These subject receive open label treatment long-acting rFVIII approximately 6 month ( long 50 exposure day ) regular schedule least every 7-days . Doses dose interval may adapt subject 's clinical need . A second group patient receive open label treatment drug 12 week regular schedule 2x/week . Patients attend treatment center routine blood sample require keep electronic diary . Subjects offer participation optional extension study collect observation least additional 50 exposure day .</brief_summary>
	<brief_title>Safety Efficacy BAY94-9027 Previously Treated Male Children With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Males &lt; 12 year age Subjects severe hemophilia A Previously treat FVIII &gt; 50 exposure day Subjects current evidence history inhibitor FVIII Any inherit acquire bleed disorder Platelet count &lt; 100,000/mm3 Creatinine &gt; 2x upper limit normal Aspartate aminotransferase ( AST ) / Alanine aminotransferase ( ALT ) &gt; 5x upper limit normal</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Factor VIII</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Pediatric</keyword>
</DOC>